Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619653 | 1.00 | RAB9A (0.59) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| Benzene SCHEMBL27716393 | 0.98 | CYP3A4 (0.61) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| SCHEMBL29096117 | 0.98 | PDGFRB (0.62) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| Chlorobenzene SCHEMBL2422422 | 0.89 | CYP3A4 (0.56) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| Butylamine SCHEMBL8656513 | 0.85 | SYK (0.49) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| SCHEMBL219324 | 0.85 | PDGFRB (0.59) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| SCHEMBL17394558 | 0.84 | CYP3A4 (0.62) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| SCHEMBL30496772 | 0.84 | RAB9A (0.51) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| Quinoline SCHEMBL10706605 | 0.84 | ALDH1A1 (0.59) | RAB9ANPC1PDGFRBPDGFRACYP3A4 | |
| Hydrochloric Acid SCHEMBL29522997 | 0.83 | PDGFRB (0.58) | RAB9ANPC1PDGFRBPDGFRACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524594-B1 | NON-SOLVATED CRYSTAL, PREPARATION METHOD AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2024-11-06 | — | — | EP | claimed |
| WO-2022247844-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PROTEIN KINASE INHIBITOR AND MEDICAL USE THEREOF | 深圳微芯生物科技股份有限公司 | 2022-12-01 | — | — | WO | claimed |
| US-20240382474-A1 | ENPP1 MODULATORS AND USES THEREOF | VIR BIOTECHNOLOGY INC (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024215817-A1 | NOVEL 5-CYCLOPROYLQUINOLINE DERIVATIVES AS PLPRO INHIBITORS | PFIZER INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586191-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-111542515-B | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2023-12-05 | — | — | CN | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382474-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | RAB9A 317/4885NPC1 2317/4885PDGFRB 2295/4885 |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | RAB9A 1262/4885NPC1 1305/4885PDGFRB 327/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | RAB9A 611/4885NPC1 1948/4885PDGFRB 3543/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | RAB9A 1262/4885NPC1 1305/4885PDGFRB 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.